A phase I/II clinical trial to evaluate the safety and immunogenicity of LIPO-5 alone, ALVAC alone, and ALVAC prime/LIPO-5 boost in healthy, HIV-1 uninfected adult participants.
Phase of Trial: Phase I/II
Latest Information Update: 03 May 2012
At a glance
- Drugs Anti-HIV lipopeptide vaccine (Primary) ; HIV vaccine vCP1452 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- 11 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Aug 2009 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.
- 28 Sep 2008 Actual start date (Jan 2004) added as reported by CT.gov